Kolmar Korea Co., Ltd.
South Korean ODM manufacturer making cosmetics and drugs for other brands, especially sunscreen.
On the record
Checkpoint: Q2 2026 earnings, with FDA bemotrizinol approval expected to lift H2 sun-care orders
The call
Kolmar Korea keeps posting record revenue and profit as K-beauty exports grow, with certification and factory ownership keeping brand clients locked in for now.
Kolmar Korea manufactures cosmetics and beauty products for major brands around the world, handling everything from creation to production at its own factories in Korea, the US, Canada, and China. It is hard to replace because it holds regulatory approvals (FDA certifications since 2013), manufacturing licenses, patents for UV protection, and long-standing relationships with big-name clients going back decades; competitors like Cosmecca and COSMAX exist but are growing in the same expanding Korean beauty market rather than stealing Kolmar's customers. The one thing that could shift the picture is if the Korean beauty market stops growing, or if family conflicts at Kolmar's parent company create instability that distracts from the business.
Why
01
AI pressure: None apparent. AI tools speed up formulation and quality testing inside Kolmar's own labs rather than threatening its manufacturing business. Could AI do the core job? Unlikely.
02
Bigger players: None apparent. No large conglomerate is displacing Kolmar; peers like COSMAX and Cosmecca Korea are growing alongside it in an expanding K-beauty market. Could a giant copy it? No, they are blocked.
03
What protects it. FDA OTC certification, CGMP/KGMP licenses, owned factories across Korea, US, Canada and China, and 100+ UV patents lock in brand clients.
What would change this call
Cosmecca Korea posts over 25% YoY growth in Q2/Q3 2026 while Kolmar growth falls below 8%. Would show peer gains are coming from share loss, not just market expansion.
Kolmar Korea reports two consecutive quarters of revenue growth under 5% YoY. Would signal a slowdown breaking its multi-year record growth streak.
Yoon family governance dispute at Kolmar Holdings resurfaces publicly after the May 2026 suit withdrawal. Would show leadership instability disrupting capital allocation and strategy.
Kolmar Korea reports two consecutive quarters of revenue growth under 5% YoY. Would signal a slowdown breaking its multi-year record growth streak.
Yoon family governance dispute at Kolmar Holdings resurfaces publicly after the May 2026 suit withdrawal. Would show leadership instability disrupting capital allocation and strategy.
Key numbers
- FY2025 revenue 2.7224 trillion won, up 11.0% YoY
- Q1 2026 net profit up 159% YoY
- Q1 2026 domestic sales up 25% YoY to 343B won
Named risks
- Family governance tension at Kolmar Holdings could resurface despite May 2026 lawsuit withdrawal.
- K-beauty export demand is cyclical and a sustained reversal would hit revenue growth.
- Faster-growing peer Cosmecca Korea (56% YoY Q1 2026) could shift rising-tide dynamics toward share loss.
- Loss of FDA OTC sunscreen certification would remove a core regulatory moat.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| COSMAX | contesting | Q1 2026 revenue 682B won, up 16% YoY, but operating profit growth lagged at 3% (2026-05-13) |
| Cosmecca Korea | gaining on | Q1 2026 revenue up 56.4% YoY to 185.1B won, faster than Kolmar's growth (2026-05-13) |
| Intercos Korea | losing to | Found guilty of stealing Kolmar sunscreen trade secrets; civil judgment against it October 2024 |
| C&C International | contesting | Smaller peer, Q1 2026 domestic sales up only 7.4% YoY (2026-05-21) |
Questions people ask
- Is Kolmar Korea profitable in 2026?
- Yes. Kolmar Korea posted FY2025 consolidated revenue of 2.7224 trillion won, up 11.0% YoY, with operating profit of 239.6 billion won, up 23.6% YoY, both record highs, reported February 22, 2026. Q1 2026 net profit reportedly surged 159% YoY on K-beauty and pharma affiliate growth.
- Who owns Kolmar Korea?
- Kolmar Korea Co., Ltd. (KRX: 161890) is publicly traded and controlled through Kolmar Holdings Co., Ltd. (KRX: 024720), a separate holding entity. A father-son ownership dispute between founder Yoon Dong-han and Vice Chairman Yoon Sang-hyun was withdrawn on May 27, 2026, leaving the son as largest shareholder of Kolmar Holdings.
- Could AI replace Kolmar Korea?
- Unlikely soon. Kolmar deploys AI internally (its 2019 smart factory cut defect rates 40-42%, and it joined a government AI Factory Alliance in October 2025), but its moat rests on FDA OTC sunscreen certification since 2013, owned factories in Korea, US, Canada and China, and 100+ UV patents, none of which AI alone can replicate.
- Is joining Kolmar Korea safe from layoffs?
- Headcount has been slowly growing, not shrinking: WSJ/FactSet reported about 1,304 employees as of January 2026, and separate third-party estimates showed roughly 1.2% growth from 2023 to 2026, even as revenue grew double digits, suggesting no reported layoffs despite automation investment.
- Who is Kolmar Korea's biggest competitor?
- Its closest peers are Korean cosmetics ODMs COSMAX and Cosmecca Korea. In Q1 2026, COSMAX posted 682 billion won revenue (+16% YoY) and Cosmecca Korea grew fastest at 56.4% YoY to 185.1 billion won, per reporting dated May 13, 2026, though all three are growing amid a K-beauty export boom rather than taking share from Kolmar.
- Did Kolmar Korea have a family ownership dispute?
- Yes. Founder Yoon Dong-han sued his son, Vice Chairman Yoon Sang-hyun, in May 2025 seeking return of about 13% of Kolmar Holdings shares gifted years earlier. Yoon Dong-han withdrew the lawsuit on May 27, 2026, ending the feud with the son retaining largest-shareholder status.
Timeline
- 2026-07-04Shinhan raises Kolmar target price to 130,000 won on FDA sunscreen catalyst; earnings surprise reported
- 2026-06-09FDA approves bemotrizinol, first new US sunscreen filter approved in 27 years
- 2026-05-27Founder Yoon Dong-han withdraws lawsuit against son, ending Kolmar Holdings share dispute
- 2026-05-21Kolmar Korea consolidates group cosmetics assets via Kolmask acquisition and Kolmar UX transfer
- 2026-05-13Kolmar, COSMAX and Cosmecca Korea all report strong Q1 2026 results amid K-beauty boom
- 2026-04-29Kolmar Group designated Korea's first cosmetics ODM large business conglomerate by FTC
- 2026-02-22Kolmar Korea reports record FY2025 revenue of 2.7224 trillion won, up 11.0% YoY
- 2025-10-27Kolmar Korea selected as sole cosmetics firm in government AI Factory Alliance (through Dec 2029)
- 2025-05Yoon Dong-han files lawsuit against son Yoon Sang-hyun over Kolmar Holdings shares
- 2024-10Civil judgment against Intercos Korea for theft of Kolmar sunscreen trade secrets
Head to head
Revision history
25 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Kolmar Korea climbs to record revenue on K-beauty, pharma gains (2026-02-22)
- Kolmar becomes 1st cosmetics ODM to join Korea's large conglomerate ranks (2026-04-29)
- Overseas demand for made-in-Korea drives K-beauty ODM plant expansion (2026-05-21)
- Kolmar Korea (KRX:161890) Revenue (2026-06-28)
- K-beauty surge lifts Korea's top ODMs past 6 trillion won as CAPA expands (2026-02-24)
- K-Beauty Sunscreen Leader Kolmar Korea Expands into Scalp and Hair Sun Care (2026-05-13)
- Appeals court confirms conviction of Intercos Korea in Kolmar Korea tech theft
- FDA sunscreen decision puts Kolmar's US ODM strategy in spotlight (2026-06-18)
- Kolmar Korea Co. Ltd. Company Profile & Executives - WSJ (2026-01-21)
- Kolmar Korea Number of Employees 2026 (2026-06-29)
- Yoon Dong-han drops share suit, ends Kolmar Korea family feud (2026-05-27)
- Kolmar Korea Selected for Government-Led 'AI Factory' Initiative (2025-10-27)